Quantcast
Last updated on April 16, 2014 at 14:39 EDT

Latest Tris Stories

2014-04-01 08:28:22

MONMOUTH JUNCTION, N.J., April 1, 2014 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative technology-based products announced several key management changes, including the new appointment of Mr. Stephen J. Kovary to the position of Vice President of Operations. Mr. Kovary brings three decades of pharmaceutical experience in the areas of manufacturing, process improvement, facilities, engineering, plant and systems management. Prior to...

2013-09-04 08:31:44

MONMOUTH JUNCTION, N.J. and CHARLOTTE, N.C., Sept. 4, 2013 /PRNewswire/ -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive licensing agreement for the commercialization of Karbinal((TM)) ER (carbinoxamine maleate) Extended-release Oral Suspension 4 mg/5 ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up. Karbinal ER is expected to be...

2013-07-10 08:27:24

First-to-market generic equivalent of ProCentra® for treatment of ADHD and narcolepsy now available in the U.S. MONMOUTH JUNCTION, N.J., July 10, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that its generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution, the first-to-market generic equivalent of ProCentra®, which is indicated for the treatment of...

2013-06-20 08:27:00

MONMOUTH JUNCTION, N.J., June 20, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has named Janet Penner as President of its new generic pharmaceuticals business. Tris' generic pharmaceuticals business, with its own distinct sales, marketing and distribution, will be responsible for commercializing Tris' Abbreviated New Drug Applications (ANDAs) while leveraging Tris' considerable...

2013-03-11 08:27:58

MONMOUTH JUNCTION, N.J., March 11, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01. Under the collaboration, POC required the successful...

2012-11-15 08:31:34

MONMOUTH JUNCTION, N.J., Nov. 15, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced the appointment of Jonathan Berlent as Vice President of Business Development. He will lead Tris' product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities. "As Tris scales up its effort to address the growing unmet need in the industry for...

2012-07-11 02:25:23

MONMOUTH JUNCTION, N.J., July 11, 2012 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug development operations, announced today that in order to meet demand for its products (approved and near term) the company has fortified its supply chain, increased manufacturing capacity and strengthened its management team. During the past two months, Tris has been fortunate to receive five new ANDA approvals from the FDA, beginning...

2012-05-31 02:25:47

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex. Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended release...

2012-05-10 02:31:18

MONMOUTH JUNCTION, N.J., May 10, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today the joining of Ms. Amanda Wohlleber as Vice President of Scale up and Technical Services effective immediately and the promotion of their key manufacturing executive, Rajul Parikh. Amanda brings more than 20 years of pharmaceutical manufacturing and tech service experience to Tris' technology and manufacturing teams. "With our continued growth and...

2011-10-12 15:28:00

Chlorinated Tris Linked to Cancer, Removed from Children's Pajamas in 1970's BERKELEY, Calif., Oct. 12, 2011 /PRNewswire-USNewswire/ -- The same chemical removed from baby pajamas in 1977 due to concerns about carcinogenicity, was officially listed as a cancer-causing chemical by the State of California on the "Prop 65 list" today. Chlorinated Tris is the most commonly used flame retardant in foam in U.S. furniture and baby products. The listing won't ban the chemical from use but...